Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYZINE PAMOATE versus PBZ SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYZINE PAMOATE versus PBZ SR.
HYDROXYZINE PAMOATE vs PBZ-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine pamoate is a piperazine derivative with antihistamine (H1 receptor antagonist) and anticholinergic properties. It also has sedative, anxiolytic, and antiemetic effects, likely mediated through suppression of subcortical regions of the central nervous system.
Antihistamine; H1-receptor antagonist that competes with histamine for binding at H1 receptor sites, thereby preventing histamine-mediated allergic responses.
Oral: 50-100 mg every 6 hours as needed for pruritus or anxiety; maximum 600 mg/day. IM: 25-100 mg every 4-6 hours as needed.
100-200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 14-25 hours) in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function; clinically relevant dosing every 4-6 hours is recommended.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of metabolites.
Primarily renal excretion (80-90% as unchanged drug) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 5-10%.
Category A/B
Category C
Antihistamine
Antihistamine